News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
The company has reported total income of Rs. 486.16 crores during the period ended September 30, 2023
The company is confident of addressing all the observations within the stipulated time
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Investment is additive to KKR’s existing health care growth strategy
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Subscribe To Our Newsletter & Stay Updated
